Ibrutinib, the first FDA-approved BTK inhibitor, has demonstrated remarkable efficacy in treating relapsed/refractory MCL, CLL, and other B-cell malignancies. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.